share_log

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3

富国银行维持Adaptimmune Therapeutics的同等权重,将目标价提高至3美元
Benzinga Real-time News ·  2022/11/14 07:36

Wells Fargo analyst Yanan Zhu maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Equal-Weight and raises the price target from $1.5 to $3.

富国银行分析师朱亚南维持Adaptimmune Therapeutics(纳斯达克股票代码:ADAP)的权重相等,并将目标股价从1.5美元上调至3美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发